Scoping med-device campaigns against a live EHR network

Med-device launches don’t have pharma’s budget. A mid-market cardiac-monitoring device might have a $150k annual marketing envelope to cover an indication launch, a sales-team enablement push, and an ongoing HCP awareness program. The same budget at a specialty pharma brand wouldn’t cover a single DTC test.

That compressed budget changes the math on audience research. Pharma teams can afford to burn a quarter-million on a Komodo or Definitive Healthcare license before they know if the campaign pencils. Device teams can’t. They need an answer on addressable-universe sizing at a tenth of the cost, and they need it in a week, not a quarter.

Three questions a device launch has to answer first

• Who’s actually in the indication? A device for treatment-resistant hypertension needs to reach the ~12k interventional cardiologists in the US who perform renal denervation procedures — not the full cardiologist universe. The specialty rollup is the first filter.
• Where are they? Device sales are regional. A rep in Chicago covers the Midwest; a rep in Boston covers the Northeast. A national audience number is useless for territory planning. You need the same brief rolled up by state or region.
• How much prescribing volume do they drive? Adjacent-prescribing volume is a proxy for device receptiveness. An HCP who writes a lot of the competitor’s oral therapy is a plausible target for the device alternative.

What an aggregate-only scope gives a device team

Scriptlane was built for exactly this use case, even though the lander copy puts pharma first. Here’s what a device marketer gets from a 30-second scoping:

• Universe number. How many HCPs in your target specialties, in your target states, are writing the adjacent therapy. Not individuals — aggregate count.
• Specialty mix. What fraction of that universe is in your primary specialty vs. adjacent specialties. This tells you whether you need a multi-specialty launch or can concentrate on one.
• Regional mix. The same count sliced by region. Drives sales territory planning and regional-meeting prioritization.
• Trigger volume. Weekly prescribing events as a proxy for patient pipeline. Useful for sizing your in-workflow activation budget.

Where device marketing is different from pharma

Three things matter more for device than for pharma:

• Procedure codes. Devices don’t have NDCs. You’re targeting around CPT codes (the interventional procedure) or HCPCS codes (the device itself). Our scoping form accepts ICD-10 for the diagnosis layer; CPT/HCPCS support is on the roadmap and available on request.
• KOL density. Device adoption is opinion-leader-driven. A single thought-leader at a large IDN can cascade adoption across a region. Our KOL query (currently in the operator UI) surfaces that.
• Territory overlays. The sales team’s territory definition has to match the marketing footprint. State-level rollups work for most teams; metro / CBSA rollups are on the roadmap for customers who need them.

A realistic device workflow on Scriptlane

Here’s how a device launch team actually uses the tool:

• Week 1: product marketing drafts a scoping brief (indication, adjacent drugs, target specialties, states). Runs it. Reviews the aggregate rollup with sales leadership. Adjusts the brief.
• Week 2: sales territory planning uses the regional rollup to allocate reps. Marketing uses the specialty rollup to decide primary vs. adjacent specialty targeting.
• Week 3: marketing hits “request brokered execution”. We introduce them to the EHR partner program most likely to reach their footprint. The partner’s activation vendor takes it from there on standard partner-program paper.

Total cost through Scriptlane: $0. The Free tier is uncapped on scopings, Match Filter runs, and NPI list size — Pro ($199/mo) is for teams that want saved libraries, share links, CSV export, and deeper analysis layered on top. Activation is billed by the partner program, not by us.

The bigger point

Device teams have been locked out of the enterprise HCP-data market by price. The self-serve scoping tier exists specifically so a launch team with a $150k budget can size their campaign without blowing a quarter of that on data licensing. The brokered execution path closes the loop back to the partner program that will actually run the campaign.

If you’re launching a device in the next 12 months and the specialty / state combination isn’t clear yet, scope it before you write the marketing plan.